{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:53:22Z","timestamp":1792522402219,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004607","name":"Guangxi Natural Science Foundation","doi-asserted-by":"publisher","award":["2017GXNSFAA198042"],"award-info":[{"award-number":["2017GXNSFAA198042"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.intimp.2025.115153","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T20:28:40Z","timestamp":1751574520000},"page":"115153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["FcRn inhibition with efgartigimod ameliorates muscle weakness and modulates dendritic cell subsets in an experimental autoimmune myasthenia gravis mouse model"],"prefix":"10.1016","volume":"162","author":[{"given":"Danli","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaole","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenxia","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manli","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianting","family":"Que","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuean","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.intimp.2025.115153_bb0005","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115153_bb0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/j.intimp.2025.115153_bb0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115153_bb0020","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10875-010-9468-4","article-title":"Neonatal fc receptor: from immunity to therapeutics","volume":"30","author":"Kuo","year":"2010","journal-title":"J. Clin. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2025.115153_bb0025","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41582-021-00547-z","article-title":"Getting specific: targeting fc receptors in myasthenia gravis","volume":"17","author":"L\u00fcnemann","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.intimp.2025.115153_bb0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.expneurol.2019.03.001","article-title":"Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis","volume":"317","author":"Huijbers","year":"2019","journal-title":"Exp. Neurol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115153_bb0035","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.4049\/jimmunol.178.8.5390","article-title":"Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade","volume":"178","author":"Liu","year":"2007","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115153_bb0040","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2470542","article-title":"Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models","volume":"21","author":"Warang","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.intimp.2025.115153_bb0045","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors","volume":"14","author":"Dalakas","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.intimp.2025.115153_bb0050","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2025.115153_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.118074","article-title":"IgG regulation through FcRn blocking: a novel mechanism for the treatment of myasthenia gravis","volume":"430","author":"Wolfe","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.intimp.2025.115153_bb0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev-immunol-061020-053707","article-title":"Dendritic cells revisited","volume":"39","author":"Cabeza-Cabrerizo","year":"2021","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115153_bb0065","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev-immunol-020711-074950","article-title":"The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting","volume":"31","author":"Merad","year":"2013","journal-title":"Annu. Rev. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2025.115153_bb0070","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jneuroim.2004.04.021","article-title":"Dendritic cells activate autologous T cells and induce IL-4 and IL-10 production in myasthenia gravis","volume":"156","author":"Adikari","year":"2004","journal-title":"J. Neuroimmunol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115153_bb0075","doi-asserted-by":"crossref","first-page":"577","DOI":"10.21037\/atm-20-918","article-title":"Glucose metabolism pattern of peripheral blood immune cells in myasthenia gravis patients","volume":"8","author":"Li","year":"2020","journal-title":"Ann. Transl. Med."},{"issue":"2","key":"10.1016\/j.intimp.2025.115153_bb0080","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.nbd.2004.03.017","article-title":"Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells","volume":"16","author":"Duan","year":"2004","journal-title":"Neurobiol. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2025.115153_bb0085","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.4049\/jimmunol.172.4.2697","article-title":"Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats","volume":"172","author":"Baggi","year":"2004","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115153_bb0090","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12950-023-00363-w","article-title":"Sodium butyrate alleviates R97\u2013116 peptide-induced myasthenia gravis in mice by improving the gut microbiota and modulating immune response","volume":"20","author":"Sun","year":"2023","journal-title":"J. Inflamm. (Lond)."},{"issue":"1","key":"10.1016\/j.intimp.2025.115153_bb0095","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13020-023-00798-6","article-title":"Astragaloside IV ameliorates experimental autoimmune myasthenia gravis by regulating CD4+T cells and altering gut microbiota","volume":"18","author":"Weng","year":"2023","journal-title":"Chin. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115153_bb0100","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/imm.12347","article-title":"Silencing miR-146a influences B cells and ameliorates experimental autoimmune myasthenia gravis","volume":"144","author":"Zhang","year":"2015","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2025.115153_bb0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.expneurol.2015.02.009","article-title":"Guidelines for standard preclinical experiments in the mouse model of myasthenia gravis induced by acetylcholine receptor immunization","volume":"270","author":"Tuzun","year":"2015","journal-title":"Exp. Neurol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115153_bb0110","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1080\/08820139.2017.1299754","article-title":"Immunization with recombinantly expressed LRP4 induces experimental autoimmune myasthenia gravis in C57BL\/6 mice","volume":"46","author":"Ulusoy","year":"2017","journal-title":"Immunol. Investig."},{"key":"10.1016\/j.intimp.2025.115153_bb0115","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/bonekey.2015.101","article-title":"Assessment of muscle mass and strength in mice","volume":"4","author":"Bonetto","year":"2015","journal-title":"Bonekey Rep."},{"key":"10.1016\/j.intimp.2025.115153_bb0120","article-title":"Measuring the strength of mice","volume":"76","author":"Deacon","year":"2013","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.intimp.2025.115153_bb0125","first-page":"277","article-title":"A new method for the measurement of muscle relaxation in white mice","volume":"152","author":"Kondziella","year":"1964","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2025.115153_bb0130","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/imm.12322","article-title":"Neutralization of interleukin-9 ameliorates symptoms of experimental autoimmune myasthenia gravis in rats by decreasing effector T cells and altering humoral responses","volume":"143","author":"Yao","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2025.115153_bb0135","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.expneurol.2013.06.012","article-title":"A mouse model of the slow channel myasthenic syndrome: neuromuscular physiology and effects of ephedrine treatment","volume":"248","author":"Webster","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.intimp.2025.115153_bb0140","series-title":"Electrodiagnosis in Diseases of Nerve and Muscle: Principles and Practice","author":"Kimura","year":"2013"},{"issue":"12","key":"10.1016\/j.intimp.2025.115153_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202249893","article-title":"Guidelines for DC preparation and flow cytometry analysis of mouse lymphohematopoietic tissues","volume":"53","author":"Amon","year":"2023","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115153_bb0150","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/jnnp-2024-334086","article-title":"Efgartigimod efficacy and safety in refractory myasthenia gravis: UK\u2019S first real-world experience","volume":"96","author":"Moniz Dion\u00edsio","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.intimp.2025.115153_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578558","article-title":"Response of refractory residual ocular symptoms to efgartigimod in generalized myasthenia gravis: a real-world case series","volume":"401","author":"He","year":"2025","journal-title":"J. Neuroimmunol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115153_bb0160","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115153_bb0165","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1084\/jem.180.6.2377","article-title":"A major histocompatibility complex class I-like fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus","volume":"180","author":"Story","year":"1994","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.intimp.2025.115153_bb0170","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1002\/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6","article-title":"Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn","volume":"29","author":"Kim","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2025.115153_bb0175","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115153_bb0180","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3389\/fimmu.2017.01785","article-title":"Immunopathogenesis in myasthenia gravis and neuromyelitis Optica","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Immunol."},{"issue":"15","key":"10.1016\/j.intimp.2025.115153_bb0185","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2008-12-180646","article-title":"Dendritic cell homeostasis","volume":"113","author":"Merad","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2025.115153_bb0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000529626","article-title":"Aberrant dendritic cell subsets in patients with myasthenia gravis and related clinical features","volume":"30","author":"Song","year":"2023","journal-title":"Neuroimmunomodulation"},{"issue":"11","key":"10.1016\/j.intimp.2025.115153_bb0195","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1038\/s41423-021-00726-4","article-title":"Dendritic cell migration in inflammation and immunity","volume":"18","author":"Liu","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115153_bb0200","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115153_bb0205","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.20.100301.064828","article-title":"Antigen presentation and T cell stimulation by dendritic cells","volume":"20","author":"Guermonprez","year":"2002","journal-title":"Annu. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115153_bb0210","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s10072-019-04213-7","article-title":"The associations of HLA-DRB1 gene polymorphisms with late-onset myasthenia gravis: a meta-analysis","volume":"41","author":"Ling","year":"2020","journal-title":"Neurol. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2025.115153_bb0215","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German neurological society","volume":"263","author":"Melzer","year":"2016","journal-title":"J. Neurol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925011439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925011439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T03:30:30Z","timestamp":1786159830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925011439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":43,"alternative-id":["S1567576925011439"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115153","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FcRn inhibition with efgartigimod ameliorates muscle weakness and modulates dendritic cell subsets in an experimental autoimmune myasthenia gravis mouse model","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115153","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115153"}}